Orbit Discovery and Endevica Bio to develop cachexia therapeutics Feb 2, 2023 - Orbit Discovery Limited has entered into a multi target research agreement with Endevica Bio Inc. ...
Scientists develop a peptide that targets lung tumors and delivers therapeutics inside cells Feb 2, 2023 - Lung cancer claims more lives each year than any other type of cancer worldwide. According...
NIH grant funds research on a powerful new approach to drug development Feb 2, 2023 - NIH MIRA grant funds biochemist Scott Lokey’s efforts to develop complex, membrane-permeable molecules as next-generation...
Lilly, Merck double down on peptide-targeted drug delivery, betting billions in biobucks on PeptiDream pacts Feb 2, 2023 - Eli Lilly and Merck & Co. have identified PeptiDream’s peptides as a way to deliver...
Amytrx Therapeutics Partners With AmbioPharm to Expand the Potential of Leukocyte-Targeting Anti-Inflammatory Human Peptides Aug 23, 2022 - Amytrx expanding their bioactive peptide platform AMTX-100 has unique specificity to target leukocytes involved in...
Peptilogics Receives FDA Fast Track Designation for an Investigational Peptide Therapeutic for the Treatment of Periprosthetic Joint Infection Aug 23, 2022 - PLG0206 has the potential to be the first approved therapy specifically indicated for the treatment...
Biosynth Carbosynth Expands Peptide Offering with Acquisition of Pepscan Aug 23, 2022 - Biosynth Carbosynth (“Biosynth”), a supplier of critical products and services to the life sciences industry,...
Iktos and Zealand Pharma to Develop Artificial Intelligence Technology for Peptide Drug Design Aug 23, 2022 - PARIS--(BUSINESS WIRE)--Iktos, a company specialized in Artificial Intelligence for new drug design, today announced a...
Bicycle Therapeutics Announces First Patient Dosed in Expansion Cohorts of Phase I/II Trial of Bicycle® Toxin Conjugate BT5528 in Patients Jun 24, 2022 - June 8, 2022 at 7:00 AM EDT PDF Version Completed Phase I dose escalation; results...
Trial of peptide-centered SARS-CoV-2 T-cell activator in B-cell deficient individuals Jun 24, 2022 - A recent phase 1/2 study under review at the Nature Portfolio journal and posted to the Research Square*...
Peptide biotech gets renewed support from Bristol Myers and others Jun 24, 2022 - The first batch of financing lasted about five years, but this time around, Sapience Therapeutics...
Positive Results from Phase 3 Trial of Dasiglucagon in Pediatric Patients with Congenital Hyperinsulinism Jun 24, 2022 - Zealand Pharma Announces Positive Results from Phase 3 Trial of Dasiglucagon in Pediatric Patients with Congenital Hyperinsulinism (CHI) Dasiglucagon met the primary...
Elicio Therapeutics Presents Design of Ongoing AMPLIFY-201 Study in Mutant KRAS-Driven Cancers May 27, 2022 - BOSTON, May 27, 2022 (GLOBE NEWSWIRE) -- Elicio Therapeutics, a clinical-stage biotechnology company developing a pipeline...
Mystery mechanism in small peptide shows big promise for fighting antibiotic-resistant bacteria May 27, 2022 - By Olivia Trani, Oak Ridge National Laboratory--- One group of peptides, known as antimicrobial peptides (AMPs), serves... Zealand Pharma’s drug for rare metabolic disease smashes phase III May 27, 2022 - After a year of slumping stock prices, Zealand Pharma is striking back, as its peptide...
FDA approves tirzepatide: A potent new drug for type 2 diabetes May 16, 2022 - The Food and Drug Administration (FDA) has approved a novel first-in-class drug to treat type...
Early Data for Peptide Vaccine Shows Promise in Metastatic Melanoma May 16, 2022 - At the American Association for Cancer Research (AACR) 2022 Annual Meeting, investigators reported encouraging efficacy and...
Scottish scientists say venom from sea snails could hold key to future painkillers Apr 8, 2022 - The cone snail’s venom contains chemicals called conotoxins, which the creature uses to paralyse its...
Mytide Therapeutics Raises $7 Million Series A Round to Transform Peptide Manufacturing with Machine Learning Mar 15, 2022 - BOSTON--(BUSINESS WIRE)--Mytide Therapeutics, a company transforming peptide manufacturing with predictive analytics and machine learning, has... Orbit Discovery and WuXi AppTec sign agreement to access peptide discovery and optimisation technologies Mar 15, 2022 - Oxford, United Kingdom, 07 March, 2022: Orbit Discovery (Orbit), a ground-breaking peptide discovery company is pleased...
FogPharma Announces Selection of Clinical Development Candidate Directly Targeting β-Catenin Mar 9, 2022 - CAMBRIDGE, Mass.--(BUSINESS WIRE)--FogPharma, a biopharmaceutical company pioneering a new class of precision medicines that could...
9 Meters Biopharma Provides Clinical Update on Two Late-Stage Pipeline Products for Short Bowel Syndrome and for Celiac Disease Mar 8, 2022 - RALEIGH, NC / ACCESSWIRE / February 28, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage...
Review: Cyclic peptide drugs approved in the last two decades (2001–2021) Mar 8, 2022 - In contrast to the major families of small molecules and antibodies, cyclic peptides, as a... 9 Meters Biopharma Announces Publication of Data on Larazotide for the Treatment of Multisystem Inflammatory Syndrome in Children (MIS-C) Mar 8, 2022 - RALEIGH, NC / ACCESSWIRE / February 25, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage... Sapience Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of ST101 Mar 8, 2022 - HARRISON, N.Y., Jan. 6, 2022 /PRNewswire/ -- Sapience Therapeutics, Inc., a biotechnology company focused on the...
Novo Nordisk launches anti-diabetes pill semaglutide in India Mar 8, 2022 - Novo Nordisk, the Danish drug maker on Thursday announced the launch of oral semaglutide in...
Asep Medical Inc. Received Army Funding for Anti-Inflammatory Peptide Technology Feb 17, 2022 - VANCOUVER, BC, Feb. 16, 2022 /PRNewswire/ - Asep Medical Holdings Inc. ("Asep Inc." or the...
ArmaGen Receives U.S. Orphan Drug Designation for AGT-184 Dec 22, 2018 - Calabasas, Calif., August 2, 2018 – ArmaGen, Inc., a privately held biotechnology company focused on...
Gritstone Oncology Announces Publication in Nature Biotechnology of Neoantigen Identification Capabilities of its Artificial Intelligence Platform, EDGE Dec 22, 2018 - EMERYVILLE, Calif., Dec. 17, 2018 (GLOBE NEWSWIRE) -- Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage...
CohBar Provides Update on CB4211 Clinical Trial Dec 22, 2018 - MENLO PARK, Calif., Nov. 05, 2018 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical...
Ironwood Pharmaceuticals Announces FDA Fast Track Designation for Praliciguat for the Treatment of Heart Failure Dec 21, 2018 - CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sep. 13, 2018-- Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a commercial biotech company, today...
Amicus Therapeutics Announces First Patient Dosed in Phase 3 PROPEL Pivotal Study of AT-GAA in Patients with Pompe Disease Dec 20, 2018 - Global Study to Assess AT-GAA Compared to Standard-of-Care Enzyme Replacement Therapy (ERT) over 52 Weeks. CRANBURY, NJ, USA I ...
AzurRx BioPharma Announces Initiation of Phase II OPTION Clinical Trial of MS1819-SD in Cystic Fibrosis Patients Dec 19, 2018 - The Phase II multi-center study is designed to investigate the safety, tolerability and efficacy of MS1819-SD in a head-to-head.. Bicycle’s First Peptide-Toxin Conjugate Enters the Clinic for Solid Tumors Jul 18, 2018 - From Labiotech.eu A collaboration between Bicycle Therapeutics and Cancer Research UK has yielded its first...
Sapience Therapeutics, Inc. Selected as a Winner of the JLABS NYC QuickFire Challenge Jul 18, 2018 - June 26, 2018 08:59 ET | Source: Sapience Therapeutics, Inc. HARRISON, N.Y., June 26, 2018 (GLOBE NEWSWIRE) --...
Startup Neuraly Raises $36M to Bring Potential Disease-Modifying Treatments to Patients with Parkinson’s Disease Jul 18, 2018 - July 18, 2018 08:00 AM Eastern Daylight Time GERMANTOWN, Md.--(BUSINESS WIRE)--Today, Neuraly announced its launch...
Novo Nordisk Inks Collab with Kallyope for Gut–Brain Axis Drug Discovery Jul 18, 2018 - From Genetic Engineering and News Novo Nordisk has announced a drug discovery collaboration with New... CohBar Initiates Clinical Study with First-in-human Dosing of CB4211, a Novel Mitochondria Based Therapeutic for the Treatment of NASH Jul 18, 2018 - July 12, 2018 09:00 ET | Source: CohBar, Inc. MENLO PARK, Calif., July 12, 2018 (GLOBE NEWSWIRE) --...
Rare endocrine disease biotech Crinetics Pharmaceuticals prices upsized IPO at $17 high end Jul 16, 2018 - Currently marketed peptide drugs require painful monthly or daily injections and, in the case of somatostatin peptide drugs, often fail to fully control the ...